In metastatic tumors, a significant downregulation of GPC6 was also detected, its levels being reduced in 87% of the cases analyzed (p < 0.05), with values being around 26% of those determined in healthy tissues (Fig. 1b and c). Here, GPC6 is linked to metastatic neoplasm.